麓鹏制药IPO:成立仅7年,凭新一代BTK抑制剂挑战礼来,后来者的野望?

医药研究社
Nov 04

后浪来袭?来源|医药研究社部分创新药企的突围,是从“打破常规”开始的。最近启动港股IPO的麓鹏制药就有相关实践。据悉,该公司成立于2018年,专注于设计、发现、临床开发及商业化超越传统药物发现“五规则”(里宾斯基五规则,传统用于指导基于分子性质设计小分子口服药物,且仅包含一个有限的化学空间部分)指南分子化学空间定义的高生物利用度口服药物,以满足全球癌症及自身免疫性疾病患者未获满足的医疗需求。沿着...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10